Trial Profile
Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Haematological malignancies
- Focus Expanded access; Therapeutic Use
- Sponsors Bellicum Pharmaceuticals
- 14 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2018 According to a Bellicum Pharmaceuticals media release, data from this trial will be presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 1-4, 2018, in San Diego, CA.
- 27 Aug 2018 New trial record